X‑Chem and Gilead Announce Drug Discovery Collaboration
WALTHAM, Mass. – November 28, 2017 – X-Chem, Inc. (X-Chem), a privately held biotechnology company applying its innovative drug discovery platform to the generation of novel small molecule therapeutics, announced today a drug discovery partnership with Gilead Sciences, Inc. (Gilead). Under the terms of the agreement, XChem will screen its proprietary DEXTM libraries, which contain >120 billion individually DNA-encoded small molecules, toward the discovery of novel, high-value therapeutic leads against targets in antiviral and additional therapeutic areas. Gilead has the option to license drug leads discovered under the collaboration, and will be responsible for further development and commercialization of the resulting programs.
AI-Powered Building Blocks “ReadiBLOX” for DEL Synthesis
Drug Hunter recently wrote the article “Decoding DNA-Encoded Libraries for Drug Discovery.” Over the past two decades, DEL technology has...
Our Services
X-Chem Services Empower Your Drug Discovery Strategy Our DNA-encoded library (DEL) expertise, medicinal chemistry experience and artificial intelligence innovations position...
Chimie Médicinale
Anglais Français Proposer des candidats réalistes avec des décennies d’expérience et un palmarès éprouvé de succès auprès des clients Avec...
Job Opportunities
Anglais Français Notre histoire X-Chem est un pionnier de la technologie des librairies chimiques encodées dans l’ADN (DEL) depuis 2009...
Internship Opportunities
Anglais Français Commencez votre carrièreavec X-Chem Les stagiaires de X-Chem font partie intégrante du succès de notre organisation, et nous...